Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis

Kawaguchi,Takumi; Itou,Minoru; Taniguchi,Eitaro; Sata,Michio

doi:10.3892/ijmm.2014.1826

Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis

Authors:
- Takumi Kawaguchi
- Minoru Itou
- Eitaro Taniguchi
- Michio Sata
View Affiliations

Affiliations: Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830‑0011, Japan
Published online on: June 27, 2014 https://doi.org/10.3892/ijmm.2014.1826
Pages: 782-787

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucagon‑like peptide‑1 (GLP‑1) is involved in the development of non‑alcoholic steatohepatitis (NASH), which is characterized by fatty acid imbalance. The aim of this study was to investigate the effects of the GLP‑1 receptor (GLP‑1R) agonist, exendin‑4 (Ex‑4), on hepatic fatty acid metabolism and its key enzyme, Δ‑5‑desaturase, in a murine model of NASH. NASH was induced in db/db mice fed a methionine‑choline deficient (MCD) diet. Ex‑4 (n=4) or saline [control (CON); n=4] was administered intraperitoneally for 8 weeks. Steatohepatitis activity was evaluated by non‑alcoholic fatty liver disease (NAFLD) activity score. Hepatic fatty acid composition and Δ‑5‑desaturase index were analyzed by gas chromatography. Ex‑4 treatment significantly reduced body weight and the NAFLD activity score. Hepatic concentrations of long‑chain saturated fatty acids (SFAs) were significantly higher in the Ex‑4 group compared to the CON group (23240±955 vs. 31710±8436 µg/g•liver, P<0.05).Ex‑4 significantly reduced hepatic n‑3 polyunsaturated fatty acid (PUFA)/n‑6 PUFA ratio compared to the CON group (13.83±3.15 vs. 8.73±1.95, P<0.05). In addition, the hepatic Δ‑5‑desaturase index was significantly reduced in the Ex‑4 group compared to the CON group (31.1±12.4 vs. 10.5±3.1, P<0.05). In conclusion, the results showed that Ex‑4 improved steatohepatitis in a murine model of NASH. Furthermore, Ex‑4 altered hepatic long‑chain saturated and PUFA composition and reduced the Δ‑5‑desaturase index. Thus, Ex‑4 may improve NASH by regulating hepatic fatty acid metabolism.

View Figures

View References

1	Williams CD, Stengel J, Asike MI, et al: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 140:124–131. 2011. View Article : Google Scholar
2	Ono M and Saibara T: Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature. J Gastroenterol. 41:725–732. 2006. View Article : Google Scholar : PubMed/NCBI
3	Sumida Y, Yoneda M, Hyogo H, et al: A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 46:257–268. 2011. View Article : Google Scholar
4	Eguchi Y, Hyogo H, Ono M, et al: Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 47:586–595. 2012. View Article : Google Scholar
5	Nakahara T, Hyogo H, Yoneda M, et al: Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. Nov 26–2013.(Epub ahead of print).
6	Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
7	Imajo K, Fujita K, Yoneda M, et al: Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 16:44–54. 2012. View Article : Google Scholar : PubMed/NCBI
8	Smith K: Microbiota: Gut microbiota produce alcohol in patients with NASH. Nat Rev Gastroenterol Hepatol. 9:6872012. View Article : Google Scholar : PubMed/NCBI
9	Mells JE and Anania FA: The role of gastrointestinal hormones in hepatic lipid metabolism. Semin Liver Dis. 33:343–357. 2013. View Article : Google Scholar : PubMed/NCBI
10	Itou M, Kawaguchi T, Taniguchi E, et al: Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. J Gastroenterol Hepatol. 23:244–251. 2008. View Article : Google Scholar : PubMed/NCBI
11	Itou M, Kawaguchi T, Taniguchi E and Sata M: Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol. 19:2298–2306. 2013. View Article : Google Scholar : PubMed/NCBI
12	Drucker DJ: The biology of incretin hormones. Cell Metab. 3:153–165. 2006. View Article : Google Scholar : PubMed/NCBI
13	Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM and Yeh MW: Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 97:121–131. 2012. View Article : Google Scholar : PubMed/NCBI
14	Broide E, Bloch O, Ben-Yehudah G, Cantrell D, Shirin H and Rapoport MJ: GLP-1 receptor is expressed in human stomach mucosa: analysis of its cellular association and distribution within gastric glands. J Histochem Cytochem. 61:649–658. 2013. View Article : Google Scholar : PubMed/NCBI
15	Gupta NA, Mells J, Dunham RM, et al: Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 51:1584–1592. 2010. View Article : Google Scholar : PubMed/NCBI
16	Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al: Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 31:1285–1297. 2011. View Article : Google Scholar
17	Trevaskis JL, Griffin PS, Wittmer C, et al: Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol. 302:G762–G772. 2012. View Article : Google Scholar : PubMed/NCBI
18	Dhanesha N, Joharapurkar A, Shah G, et al: Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice. Eur J Pharmacol. 714:188–192. 2013. View Article : Google Scholar : PubMed/NCBI
19	Panjwani N, Mulvihill EE, Longuet C, et al: GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(−/−) mice. Endocrinology. 154:127–139. 2013.PubMed/NCBI
20	Stumpf PK: Metabolism of fatty acids. Annu Rev Biochem. 38:159–212. 1969. View Article : Google Scholar
21	Calder PC: N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids. 38:343–352. 2003. View Article : Google Scholar : PubMed/NCBI
22	Patterson E, Wall R, Fitzgerald GF, Ross RP and Stanton C: Health implications of high dietary omega-6 polyunsaturated Fatty acids (Review). J Nutr Metab. 2012:e5394262012. View Article : Google Scholar
23	Puri P, Baillie RA, Wiest MM, et al: A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 46:1081–1090. 2007. View Article : Google Scholar : PubMed/NCBI
24	Puri P, Wiest MM, Cheung O, et al: The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology. 50:1827–1838. 2009. View Article : Google Scholar : PubMed/NCBI
25	Poudel-Tandukar K, Sato M, Ejima Y, et al: Relationship of serum fatty acid composition and desaturase activity to C-reactive protein in Japanese men and women. Atherosclerosis. 220:520–524. 2012. View Article : Google Scholar : PubMed/NCBI
26	Chuang LT, Thurmond JM, Liu JW, Mukerji P, Bray TM and Huang YS: Effect of conjugated linoleic acid on Delta-5 desaturase activity in yeast transformed with fungal Delta-5 desaturase gene. Mol Cell Biochem. 265:11–18. 2004. View Article : Google Scholar
27	Roke K, Ralston JC, Abdelmagid S, et al: Variation in the FADS1/2 gene cluster alters plasma n-6 PUFA and is weakly associated with hsCRP levels in healthy young adults. Prostaglandins Leukot Essent Fatty Acids. 89:257–263. 2013. View Article : Google Scholar : PubMed/NCBI
28	Maniongui C, Blond JP, Ulmann L, Durand G, Poisson JP and Bézard J: Age-related changes in delta 6 and delta 5 desaturase activities in rat liver microsomes. Lipids. 28:291–297. 1993. View Article : Google Scholar : PubMed/NCBI
29	Kröger J and Schulze MB: Recent insights into the relation of Δ5 desaturase and Δ6 desaturase activity to the development of type 2 diabetes. Curr Opin Lipidol. 23:4–10. 2012.
30	López-Vicario C, González-Périz A, Rius B, et al: Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut. 63:344–355. 2014.
31	Yamaguchi K, Yang L, McCall S, et al: Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 45:1366–1374. 2007. View Article : Google Scholar
32	Kawaguchi T, Sakisaka S, Sata M, Mori M and Tanikawa K: Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis. Hepatology. 29:205–216. 1999. View Article : Google Scholar : PubMed/NCBI
33	Kawaguchi T, Sakisaka S, Mitsuyama K, et al: Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. Hepatology. 31:1285–1295. 2000. View Article : Google Scholar
34	Kawaguchi T, Yoshida T, Harada M, et al: Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 165:1499–1508. 2004. View Article : Google Scholar : PubMed/NCBI
35	Kawaguchi T, Ide T, Taniguchi E, et al: Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 102:570–576. 2007. View Article : Google Scholar : PubMed/NCBI
36	Krishna SM, Seto SW, Moxon JV, et al: Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model. Am J Pathol. 181:706–718. 2012. View Article : Google Scholar
37	Kleiner DE, Brunt EM, Van Natta M, et al: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI
38	Folch J, Lees M and Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 226:497–509. 1957.PubMed/NCBI
39	Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N and Harrison SA: Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol. 105:2707–2709. 2010. View Article : Google Scholar : PubMed/NCBI
40	Ding X, Saxena NK, Lin S, Gupta NA and Anania FA: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 43:173–181. 2006. View Article : Google Scholar : PubMed/NCBI
41	Gupta NA, Kolachala VL, Jiang R, et al: The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. Am J Pathol. 181:1693–1701. 2012. View Article : Google Scholar : PubMed/NCBI
42	Leamy AK, Egnatchik RA and Young JD: Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res. 52:165–174. 2013. View Article : Google Scholar : PubMed/NCBI
43	Matsumori R, Miyazaki T, Shimada K, et al: High levels of very long-chain saturated fatty acid in erythrocytes correlates with atherogenic lipoprotein profiles in subjects with metabolic syndrome. Diabetes Res Clin Pract. 99:12–18. 2013. View Article : Google Scholar
44	Kusunoki M, Tsutsumi K, Nakayama M, et al: Relationship between serum concentrations of saturated fatty acids and unsaturated fatty acids and the homeostasis model insulin resistance index in Japanese patients with type 2 diabetes mellitus. J Med Invest. 54:243–247. 2007. View Article : Google Scholar
45	Arrol S, Mackness MI and Durrington PN: The effects of fatty acids on apolipoprotein B secretion by human hepatoma cells (HEP G2). Atherosclerosis. 150:255–264. 2000. View Article : Google Scholar : PubMed/NCBI
46	Kurek K, Piotrowska DM, Wiesiolek-Kurek P, et al: Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver Int. Sep 25–2013.(Epub ahead of print).
47	Araya J, Rodrigo R, Videla LA, et al: Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond). 106:635–643. 2004. View Article : Google Scholar
48	de Gomez Dumm IN, de Alaniz MJ and Brenner RR: Effect of dietary fatty acids on delta 5 desaturase activity and biosynthesis of arachidonic acid in rat liver microsomes. Lipids. 18:781–788. 1983.PubMed/NCBI